Department of Endocrinology and Metabolism, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China.
Department of Critical Care Medicine, Inner Mongolia People's Hospital, Hohhot, Inner Mongolia 010017, P.R. China.
Oncol Rep. 2019 Nov;42(5):1981-1995. doi: 10.3892/or.2019.7314. Epub 2019 Sep 16.
Lung cancer is the leading cause of cancer mortality worldwide. Approximately 85% of all lung cancer cases are classified as non‑small cell lung cancer (NSCLC). Currently, there is no standard method to predict the survival of patients with NSCLC. Insulin‑like growth factor‑binding proteins (IGFBPs) function as modulators of IGF signaling and are attracting increasing attention for their role in NSCLC. However, the prognostic values of individual IGFBPs in NSCLC, particularly at the mRNA level, remain unknown. In the present study, the distinct expression patterns and prognostic values of IGFBP family members in patients with NSCLC through bioinformatics analysis were reported using a series of databases, including Gene Expression Profiling Interactive Analysis, Kaplan‑Meier Plotter, cBioPortal, GeneMANIA, and the Database for Annotation, Visualization and Integrated Discovery. In patients with NSCLC, IGFBP2 and IGFBP3 were significantly upregulated, while IGFBP6 was downregulated. High IGFBP1/2/4 expression was correlated with poor overall survival (OS) in all NSCLC types, especially adenocarcinoma; however, high IGFBP2/5 expression was significantly correlated with favorable OS only in patients with squamous cell carcinoma. In addition, aberrant IGFBP1/2/3/4/5 mRNA levels were associated with the prognosis of subsets of NSCLC with different clinicopathological features. These results indicated that various IGFBPs can serve as useful prognostic biomarkers and as potential targets for NSCLC therapies.
肺癌是全球癌症死亡的主要原因。大约 85%的肺癌病例被归类为非小细胞肺癌 (NSCLC)。目前，尚无预测 NSCLC 患者生存的标准方法。胰岛素样生长因子结合蛋白 (IGFBPs) 作为 IGF 信号的调节剂，其在 NSCLC 中的作用引起了越来越多的关注。然而，IGFBPs 个体在 NSCLC 中的预后价值，特别是在 mRNA 水平上，仍然未知。在本研究中，通过一系列数据库（包括基因表达谱交互分析、Kaplan-Meier Plotter、cBioPortal、GeneMANIA 和数据库注释、可视化和综合发现）进行了生物信息学分析，报告了 IGFBP 家族成员在 NSCLC 患者中的不同表达模式和预后价值。在 NSCLC 患者中，IGFBP2 和 IGFBP3 显著上调，而 IGFBP6 下调。IGFBP1/2/4 高表达与所有 NSCLC 类型（尤其是腺癌）的总生存期 (OS) 不良相关；然而，IGFBP2/5 高表达仅与鳞状细胞癌患者的良好 OS 显著相关。此外，异常的 IGFBP1/2/3/4/5 mRNA 水平与不同临床病理特征的 NSCLC 亚组的预后相关。这些结果表明，各种 IGFBPs 可以作为有用的预后生物标志物，并作为 NSCLC 治疗的潜在靶点。
